Vanzacaftor

Vertex Pharmaceuticals announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor/deutivacaftor, a once-daily triple combination therapy for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor is also undergoing regulatory review in multiple other jurisdictions, including by the Food and Drug Administration (FDA) in the U.S. and by the European Medicines Agency (EMA) in the E.U.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.